The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Corcept sees 40% growth in 2025 revenue with promising trials, expanded patient base, and strong projections. Read my ...

INX-315 is an oral, investigational selective cyclin-dependent kinase 2 (CDK2) inhibitor. The designation was based on preclinical data as well as interim data from the ongoing phase 1/2 INX-315-01 ...

Corcept attributed the revenue shortfall to supply chain issues at its specialty pharmacy vendor early in the quarter, which impacted its ability to fulfill a surge in demand. The company noted that ...

A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a ...

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 Corcept Therapeutics Incorporated (NASDAQ: CORT), a ...

Corcept is studying relacorilant in a variety of serious disorders in addition to ovarian cancer, including endogenous hypercortisolism (Cushing’s syndrome) and prostate cancer. Relacorilant is ...

Corcept Therapeutics Incorporated (NASDAQ ... plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.